ftInvstr

CORONA · Healthcare ₹2094.0 -1.87% Mkt Cap ₹12791 Cr overvalued

CORONA

Healthcare Drug Manufacturers - General

★ Watchlist ⧉ Add to bucket

₹2094.0

-1.87% today · 30d +2.6%

as of 2026-09-04

Price · Daily Candles

Detect candlestick pattern

AI narrative is temporarily unavailable for CORONA. The deterministic sections below render from live data.

₹ Latest Earnings · Q ending 2026-06-30

REVENUE

₹422 Cr

NET PROFIT

₹60 Cr

OPM

22.62%

EPS

₹9.83

PE 63.64

Intrinsic value · DCF ₹578.49 · Margin of safety -72.4% (overvalued) · FCF yield 0.43%

◇ Sector Position

PEERPEROCE %

CORONA63.6433.0

GLAXO46.8657.97

RUBICON101.0127.36

PFIZER28.6424.29

+ 2 more peers — sign in to view

ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

SCORE / 100

Overall

6-axis composite of the sections below.

Performance — —

Valuation STRETCHED 20

Growth STRONG 76

Profitability HIGH 88

Technicals NEUTRAL 67

Risk LOW 90

Key Stats

TTM PE

63.64

P/B

16.96

52W HIGH

₹2270.1

OFF HIGH

-7.76%

DIV YIELD

0.48%

MKT CAP

₹12791 Cr

◉ Active Signals

MACDNeutral-6.9774

RSI(14)Neutral51.15

Street Consensus

3 analysts

₹2304.67

mean target

Low ₹2175.0Now ₹2094.0High ₹2479.0

⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold CORONA and at what entry.